ReviewInternational journal of dermatology2026
Spatial Proteomics as a Potential Decision-Support Layer for Early Melanoma: A Narrative Review.
Review in International journal of dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Distinguishing early melanoma from borderline, atypical, or biologically intermediate melanocytic lesions remains one of the most consequential and urgent diagnostic challenges in dermato-oncology, since melanoma causes nearly 95% of skin cancer deaths. This narrative review establishes the biological relevance and evaluates the clinical maturity of mass spectrometry-based proteomics, with particular emphasis on spatially resolved approaches, as a powerful strategy to address this critical diagnostic gap. We position spatial proteomics within the broader landscape of DNA-, RNA-, and protein-based molecular diagnostics for functional manifestation, highlighting that genomic and transcriptomic methods offer standardized, higher-throughput workflows but limited insight into the tumor microenvironment and functional protein-level biology. Laser capture microdissection-mass spectrometry, imaging mass spectrometry, and Deep Visual Proteomics each preserve spatial and single-cell resolution. However, protein expression is inherently plastic, shaped by microenvironment, tissue handling, and technical artifact, and no existing study has been powered specifically for the diagnostically indeterminate categories where clinical need is greatest. We discuss how compartment-resolved "mitochondrial-high" profiles and "immune-low" microenvironment states, evidence largely extrapolated from progression and metastatic biology, might inform future risk stratification. Spatial proteomics represents a biologically promising, but not yet clinically validated, extension of morphology-led melanoma diagnosis, with the potential to resolve functional states within annotated tumor compartments. Integrated with AI-guided tissue annotation, compartment-resolved mass spectrometry and spatial proteomic profiling could, following prospective validation, help improve the distinction between borderline melanocytic lesions and melanoma while refining patient risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.